title: Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.
abstract: BACKGROUND
  Trastuzumab plus chemotherapy has become the standard of care for women with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Trastuzumab-based pre-operative systemic (neo-adjuvant) therapy (PST) also appears promising, warranting further investigation.
  
  
  METHODS
  Patients with HER2-positive, stage II/III non-inflammatory, operable breast cancer requiring a mastectomy (but who wished to conserve the breast) received weekly trastuzumab and 3-weekly docetaxel for six cycles before surgery. The primary end point was pathological complete response (pCR) rate, determined from surgical specimens.
  
  
  RESULTS
  Thirty-three patients were enrolled. The majority (79%) had T2 tumors, with 42% being N1/2. Twenty-nine patients completed six cycles of therapy and one patient withdrew prematurely due to progressive disease. A complete or partial objective clinical response was seen in 96% (73% and 23%, respectively) of patients. Surgery was performed in 30 patients, breast conserving in 23 (77%). In an intention-to-treat analysis, tumor and nodal pCR was seen in 14 (47%) patients. Treatment was generally well tolerated. Grade 3/4 neutropenia occurred in 85% of patients while febrile neutropenia was encountered in 18%. Only three patients withdrew prematurely due to toxicity. No symptomatic cardiac dysfunction was reported.
  
  
  CONCLUSIONS
  PST with trastuzumab plus docetaxel achieved promising efficacy, with a high pCR rate and good tolerability, in women with stage II or III HER2-positive breast cancer.
authors.affiliation: Oncology, Surgery, Radiology CAC GF Leclerc, Dijon, France. bcoudert@dijon.fnclcc.fr
authors.forename: B P
authors.initials: BP
authors.lastname: Coudert
authors.forename: L
authors.initials: L
authors.lastname: Arnould
authors.forename: L
authors.initials: L
authors.lastname: Moreau
authors.forename: P
authors.initials: P
authors.lastname: Chollet
authors.forename: B
authors.initials: B
authors.lastname: Weber
authors.forename: L
authors.initials: L
authors.lastname: Vanlemmens
authors.forename: C
authors.initials: C
authors.lastname: Moluçon
authors.forename: N
authors.initials: N
authors.lastname: Tubiana
authors.forename: S
authors.initials: S
authors.lastname: Causeret
authors.forename: J-L
authors.initials: JL
authors.lastname: Misset
authors.forename: S
authors.initials: S
authors.lastname: Feutray
authors.forename: D
authors.initials: D
authors.lastname: Mery-Mignard
authors.forename: J
authors.initials: J
authors.lastname: Garnier
authors.forename: P
authors.initials: P
authors.lastname: Fumoleau
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D000077143:Docetaxel; D005260:Female; D018734:Genes, erbB-2; D006801:Humans; D008875:Middle Aged; D011300:Preoperative Care; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D043823:Taxoids; D000077143:Docetaxel; D000068878:Trastuzumab